<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00952237</url>
  </required_header>
  <id_info>
    <org_study_id>D0227</org_study_id>
    <nct_id>NCT00952237</nct_id>
  </id_info>
  <brief_title>Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF</brief_title>
  <official_title>Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We postulate that the combination of IL-2 and GM-CSF immunotherapy will efficiently mobilize&#xD;
      autologous peripheral blood stem cells and activated immune effector cells in patients with a&#xD;
      hematologic malignancy. These activated effector cells will improve the immune function of&#xD;
      the graft. These hypotheses will be tested using this proposed clinical trial to mobilize&#xD;
      autologous peripheral blood stem cells pre-transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Can IL-2 be administered with GM-CSF to efficiently mobilize autologous peripheral blood stem cells. This study will determine the maximum tolerated dose of IL-2 and the optimal biological dose with GM-CSF for stem cell mobilization.</measure>
    <time_frame>5 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and APBSCT.</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>IL-2 and GM-CSF for Mobilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.&#xD;
G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis.</description>
    <arm_group_label>IL-2 and GM-CSF for Mobilization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.&#xD;
Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).&#xD;
Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above</description>
    <arm_group_label>IL-2 and GM-CSF for Mobilization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients must have pathologic diagnosis of one of the following malignancies:&#xD;
             Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma or other plasma cell&#xD;
             dyscrasia (Waldenstrom, Amyloidosis), Leukemia (AML, ALL, CLL)&#xD;
&#xD;
          -  Prior Treatment: &gt; 2 weeks prior to initiation of therapy.&#xD;
&#xD;
          -  Performance Status: Karnofsky &gt; 70%&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Life Expectancy &gt; 4 months&#xD;
&#xD;
          -  Bone Marrow: bone marrow biopsy and aspirate&#xD;
&#xD;
          -  Blood counts: The patient must have adequate bone marrow function, i.e. a total WBC of&#xD;
             &gt; 2,000/ul, a Hgb of &gt; 7 mg/dl, and a platelet count of &gt; 50,000/ul, unless this&#xD;
             abnormality is believed to be due to the underlying disease.&#xD;
&#xD;
          -  Pulmonary function tests: DLCO &gt; 55% predicted.&#xD;
&#xD;
          -  Cardiac: Left ventricular ejection fraction of &gt; 40% by radionuclide scan or&#xD;
             echocardiography.&#xD;
&#xD;
          -  Liver function tests (bilirubin, alkaline phosphatase, and SGOT/SGPT) &lt; 3 x normal&#xD;
             (unless believed to be elevated due to disease).&#xD;
&#xD;
          -  No significant co-morbid medical or psychiatric illness that would significantly&#xD;
             compromise the patient's clinical care and chances of survival.&#xD;
&#xD;
          -  Informed Consent: Informed consent must be signed prior to the treatment. Patients&#xD;
             must be aware of the neoplastic nature of their disease and willingly consent after&#xD;
             being informed of the procedure to be followed, the nature of the therapy,&#xD;
             alternatives, potential benefits, side effects, risks and discomforts. The patient is&#xD;
             not deemed eligible if there is any other serious medical or psychiatric illness that&#xD;
             would prevent informed consent. (Human protection committee approval of this protocol&#xD;
             and a consent form is required.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical, social, or psychological factors which would prevent the patient from&#xD;
             receiving or cooperating with the full course of therapy.&#xD;
&#xD;
          -  Evidence on physical exam, LP, CT, or MRI scans of CNS involvement with malignancy.&#xD;
&#xD;
          -  Uncontrolled or severe cardiovascular disease, including recent (&lt; 6 months)&#xD;
             myocardial infarction, congestive heart failure, angina (symptomatic despite optimal&#xD;
             medical management), life-threatening arrhythmia, or hypertension or clinically&#xD;
             significant obstructive/restrictive pulmonary disease.&#xD;
&#xD;
          -  Serology positive for HIV&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  Concurrent or expected need for therapy with systemic corticosteroids (since systemic&#xD;
             steroids may suppress the effects of IL-2).&#xD;
&#xD;
          -  Current and clinically significant pleural effusion, pericardial effusion, or ascites.&#xD;
&#xD;
          -  Positive pregnancy test or presence of lactation.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Documented hypersensitivity to any of the drugs used in the protocol.&#xD;
&#xD;
          -  No concomitant, ongoing malignancy that is life-threatening, based on PI's evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth R Meehan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Kenneth Meehan</investigator_full_name>
    <investigator_title>Director, Bone Marrow Transplant Program</investigator_title>
  </responsible_party>
  <keyword>Autologous Peripheral Blood Stem Cell Transplant</keyword>
  <keyword>IL-2</keyword>
  <keyword>GM-CSF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Paraproteinemias</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

